Longevity & AgingSenolytics and Bone-Building Drugs Could Team Up to Reverse Age-Related Bone Loss
Osteoporosis treatment has evolved from simply slowing bone loss to actively rebuilding bone with anabolic drugs. Yet critical gaps remain: responses vary widely among older adults, gains fade over time, and the aging bone environment blunts treatment success. This review from the University of Arizona explores cellular senescence as the missing link. Senescent cells accumulate in aging bone, driving inflammation, suppressing bone-forming osteoblasts, boosting bone-dissolving osteoclasts, and promoting marrow fat. Preclinical data show that clearing these cells can prevent or reverse age-related bone loss. Early human trials of senolytics hint that benefit depends on how many senescent cells a patient carries at baseline. The authors propose combining proven anabolic therapies with senolytic or senescence-modulating agents, guided by biomarkers of senescent cell burden, to sustain skeletal resilience well into old age.
